Institute for Medical Microbiology, Jena University Hospital, 07747 Jena, Germany.
Institute of Infectious Diseases and Infection Control, Jena University Hospital, 07747 Jena, Germany.
Int J Mol Sci. 2023 Nov 14;24(22):16308. doi: 10.3390/ijms242216308.
Methicillin-sensitive () (MSSA) bacteremia remains a global challenge, despite the availability of antibiotics. Primary treatments include β-lactam agents such as cefazolin and flucloxacillin. Ongoing discussions have focused on the potential synergistic effects of combining these agents with rifampicin or fosfomycin to combat infections associated with biofilm formation. Managing staphylococcal infections is challenging due to antibacterial resistance, biofilms, and 's ability to invade and replicate within host cells. Intracellular invasion shields the bacteria from antibacterial agents and the immune system, often leading to incomplete bacterial clearance and chronic infections. Additionally, can assume a dormant phenotype, known as the small colony variant (SCV), further complicating eradication and promoting persistence. This study investigated the impact of antibiotic combinations on the persistence of 6850 and its stable small colony variant (SCV strain JB1) focusing on intracellular survival and biofilm formation. The results from the wild-type strain 6850 demonstrate that β-lactams combined with RIF effectively eliminated biofilms and intracellular bacteria but tend to select for SCVs in planktonic culture and host cells. Higher antibiotic concentrations were associated with an increase in the zeta potential of , suggesting reduced membrane permeability to antimicrobials. When using the stable SCV mutant strain JB1, antibiotic combinations with rifampicin successfully cleared planktonic bacteria and biofilms but failed to eradicate intracellular bacteria. Given these findings, it is reasonable to report that β-lactams combined with rifampicin represent the optimal treatment for MSSA bacteremia. However, caution is warranted when employing this treatment over an extended period, as it may elevate the risk of selecting for small colony variants (SCVs) and, consequently, promoting bacterial persistence.
耐甲氧西林敏感金黄色葡萄球菌(MSSA)菌血症仍然是一个全球性的挑战,尽管有抗生素可用。主要的治疗方法包括β-内酰胺类药物,如头孢唑林和氟氯西林。目前的讨论集中在将这些药物与利福平或磷霉素联合使用以对抗与生物膜形成相关的感染的潜在协同作用。由于抗菌药物耐药性、生物膜和金黄色葡萄球菌能够侵入和在宿主细胞内复制,管理葡萄球菌感染具有挑战性。细胞内入侵使细菌免受抗菌药物和免疫系统的影响,通常导致不完全清除细菌和慢性感染。此外,金黄色葡萄球菌可以呈现休眠表型,称为小菌落变异体(SCV),这进一步增加了根除的难度并促进了其持续存在。本研究调查了抗生素组合对 6850 及其稳定的小菌落变异体(SCV 菌株 JB1)的持久性的影响,重点关注细胞内存活和生物膜形成。野生型菌株 6850 的结果表明,β-内酰胺类药物与利福平联合有效地消除了生物膜和细胞内细菌,但在浮游培养物和宿主细胞中倾向于选择 SCVs。较高的抗生素浓度与金黄色葡萄球菌的 ζ 电位增加相关,表明对抗生素的膜通透性降低。当使用稳定的 SCV 突变株 JB1 时,利福平与抗生素的组合成功清除浮游细菌和生物膜,但未能根除细胞内细菌。鉴于这些发现,有理由报告β-内酰胺类药物与利福平联合使用是治疗 MSSA 菌血症的最佳选择。然而,当长期使用这种治疗方法时需要谨慎,因为它可能会增加选择小菌落变异体(SCVs)的风险,从而促进细菌的持续存在。